New Product Launches Planned for Biotech Week Boston, Oct. 4-7

PORT WASHINGTON, N.Y., September 28, 2016 - At next week’s first annual Biotech Week Boston (October 4-7, 2016), Pall Corporation, a global leader in filtration, separation and purification, will officially launch new production-scale technologies and preview upcoming technologies that enable fully continuous biopharmaceutical processing using single-use formats. These solutions will be formally introduced at the BioProcess International Conference & Exhibition (BPI), October 4 - 7, 2016 at the Boston Convention and Exhibition Center (BCEC), Booth #521.

 

As manufacturers of biotherapies seek to incorporate continuous technologies in production to improve efficiency over batch methods, and to enable process intensification, Pall is forging ahead by offering biopharmaceutical companies an “end-to-end” continuous processing option with integrated single-use technologies. Single-use systems enable manufacturers to reduce costs by eliminating cleaning and validation requirements, as well as hardware infrastructure.

 

Last year Pall introduced the Cadence™ BioSMB PD System, the first disposable flow path, continuous multi-column chromatography system that is scalable from laboratory process development to GMP manufacturing. Earlier this year, Pall introduced the Cadence Acoustic Separator (CAS)1, a groundbreaking invention that incorporates acoustic wave separation (AWS) technology to continuously harvest biologic drug substances from cell culture processes. At BPI Pall will continue to advance its pipeline of products that enable continuous manufacturing by launching production-scale continuous chromatography solutions, a new single-use stirred tank bioreactor, single-use sterile genderless connectors, and other equipment and materials. In addition, Pall will feature filtration technology for consistent and robust small virus retention.

 

“At Pall we are helping the industry move continuous bioprocessing from theory to reality,” said Michael Egholm, Ph.D., VP and General Manager, Pall BioPharmaceuticals. “Our continuous-ready products and integration expertise help manufacturers of biotherapeutics achieve high-quality products with smaller production footprints and shorter lead times.”

 

Egholm will introduce Steve Wozniak, Apple Co-Founder as the keynote speaker for the conference program at Biotech Week Boston on Friday, October 7, at 9:15am. Wozniak’s presentation will cover innovation and customer centricity. (Please find details below)

 

As the Presidential Sponsor of Biotech Week Boston, Pall also will host, present and participate in a number of activities at the BCEC, including the following:

 

  • Tuesday, Oct. 4 - 9:00am – 5:00pm
    Symposium on Continuous Processing – sponsored by Pall Life Sciences
    Topics will include GMP implementation, regulatory and quality considerations, and making the business case for continuous processing. The symposium will include case studies presented by Merck, Merrimack Pharmaceuticals, CMC Biologics, Biogen, Just Therapeutics and others.

    Pall speakers at this daylong workshop will include:
    • Marc Bisschops, Ph.D., Principal Scientist, , Pall Life Sciences, Holland
    • Mark Schofield, Ph.D., Principal R&D Engineer, Pall Life Sciences
    • Peter Levison, Senior Marketing Director – Downstream Processing, Pall Life Sciences
  • Tuesday, Oct. 4 - 7:30pm – 10:30pm
    BPI "Bio Brew" Networking Event at the Harpoon Brewery
    Pall will co-sponsor this event with Kaneka Corporation. Pall and Kaneka recently entered into a collaborative agreement for Pall to supply Kaneka’s Protein A chromatography resin (KANEKA KanCapA). A shuttle outside the BCEC will be available to transport attendees (pre-registration is required).
  • Wednesday, Oct. 5 - 9:30am – 10:30am
    Pall Presentation
    “An update on significant technology advances enabling integrated continuous bioprocessing,” presented by Martin Smith, Ph.D., Chief Technology Officer, Pall Corporation and Michael Egholm, Ph.D., VP and General Manager, Pall Life Sciences.
  • Wednesday, Oct. 5 - 11:30am – 12:00pm
    Pall Presentation
    “End-to-End Integrated Continuous BioProcessing Platform for Biologics Manufacturing,” presented by Engin Ayturk, Ph.D., Senior Manager R&D, BioPharm Applications R&D, Pall Corporation.
  • Friday, Oct. 7 - 9:15am – 10:15am
    Keynote address by Apple Co-Founder Steve Wozniak
    Topic: Innovation & Customer Centricity. Steve will be introduced by Pall’s Michael Egholm.
  • Friday, Oct. 7 - 10:15am (Pall’s Lounge, Booth #621)
    Steve Wozniak Meet & Greet
    Steve will be available for a brief period to meet with expo attendees.

 

In addition to finding Pall representatives at the company’s main booth (#521), show and conference attendees can also enjoy free refreshments at Pall’s neighboring lounge, Booth #621 and visit Booth #1355 for Pall’s technologies and services dedicated to cell and gene therapy, and vaccines. A highlight of the Cell and Gene Therapy sessions at the BPI conference will be “Achieving Large-Scale GMP Production of Adenovirus in the iCellis 500 Fixed-Bed Bioreactor.” This presentation by FinVector Vision Therapies will detail the use of the Pall iCELLis single-use perfusion bioreactor system. It will take place on Wednesday, October 5, at 2:15pm in the Gene Therapy Development & Production – Manufacturing Strategies and Solutions for Gene Therapies track.

 

About Pall Corporation

 

Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. For more information visit www.pall.com.

 

Or follow us on social media:

 

Google+ YouTube LinkedIn Twitter Facebook

 

1 On June 15, 2015, Pall announced an exclusive licensing agreement with FloDesign Sonics for acoustic wave separation, a disruptive technology for cell culture clarification for both fed-batch and perfusion applications.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160928006492/en/

Pall Life Sciences Marketing:
Erin C. Bush
Senior Manager, Global Product Marketing
erin_bush@pall.com

More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
July 2019
July 16, 2019: Servier chooses Pall as exclusive technology and services provider for planned Bio-S biomanufacturing facility in France
April 2019
April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors
March 2019
March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies
March 13, 2019: Pall Biotech to distribute ARTeSYN’s standard hardware and liner components for fluid flow control. Customers to benefit from the flexibility, agility and reliability required for their bioprocessing journey, with accelerated implementation of robust and standardized single-use fluid management and control
March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies
December 2018
December 18, 2018: New centre to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, and to provide technology solutions that meet current needs, while offering some of the most progressive technological solutions for the future
November 2018
November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing
October 2018
October 2, 2018: New centre will work to enhance drug production and empower the future workforce, reinforcing Pall's commitment to continuously improve bioprocesses through strategic partnerships
September 2018
September 24, 2018: New collaboration to see G-CON PODs customized with Pall technologies, addressing customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing
September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development